We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Infinity Pharmaceuticals, Inc. (“Infinity” or the “Company”) (NASDAQ: INFI), in connection with its proposed merger with MEI Pharma, Inc. (NASDAQ: MEIP) (“MEI Pharma”). Under the terms of the merger agreement, Infinity will become a wholly owned subsidiary of MEI Pharma.  Pursuant to an exchange ratio set forth in the merger agreement, MEI Pharma shareholders are expected to own approximately 58.0% and Infinity shareholders are expected to only own approximately 42.0% of the outstanding equity of the combined company immediately following the merger.

Weiss Law is investigating whether (i) Infinity’s board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction, (ii) the merger consideration adequatelyc ompensates Infinity shareholders, and (iii) all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.